New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 11, 2014
08:08 EDTLLYEli Lilly's Cyramza for liver cancer did not meet Phase III primary endpoint
Eli Lilly announced that the Phase III REACH trial of Cyramza in patients with hepatocellular carcinoma or liver cancer, did not meet its primary endpoint; overall survival favored the Cyramza arm but was not statistically significant. There were meaningful improvements in key secondary endpoints of progression-free survival, overall response rate and time to progression. The trial compared Cyramza plus best supportive care to placebo plus best supportive care as a second-line treatment in patients with hepatocellular carcinoma after being treated with sorafenib in the first-line setting. No Phase III study of liver cancer has been able to demonstrate improved survival in the second-line setting. Lilly plans to present data from the REACH trial at a scientific meeting later this year.
News For LLY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 30, 2015
09:29 EDTLLYEli Lilly sees ForEx to have a negative impact of 4c in 2015 EPS
Subscribe for More Information
07:20 EDTLLYEli Lilly CEO Lechleiter says currency fluctuations hitting topline
Subscribe for More Information
06:38 EDTLLYEli Lilly reports Q4 Cialis sales $622.4M vs. $588.3M last year
Subscribe for More Information
06:30 EDTLLYEli Lilly FY15 EPS guidance does not include 12c potential charge
Subscribe for More Information
06:28 EDTLLYEli Lilly backs FY15 EPS view of $3.10-$3.20, consensus $3.18
Lowers FY15 revenue guidance to $19.5B-$20B from $20.3B-$20.8B, consensus $20.67B.
06:26 EDTLLYEli Lilly reports Q4 EPS 75c, consensus 74c
Subscribe for More Information
January 29, 2015
15:37 EDTLLYNotable companies reporting before tomorrow's open
Subscribe for More Information
13:36 EDTLLYEli Lilly volatility elevated into Q4 and outlook
Subscribe for More Information
13:29 EDTLLYEarnings Preview: Eli Lilly to report Q4 results amid new product launches
Subscribe for More Information
12:00 EDTLLYLeerink biotech analysts hold an analyst/industry conference call
Biotech Analyst Schwartz discusses Biogen Idec BIIB037 and whether 2015 will be the year when Amyloid Beta is finally validated as a disease-modifying target in Alzheimer's Disease on an Analyst/Industry conference call to be held on February 3 at 2 pm.
January 21, 2015
10:16 EDTLLYLeerink biopharma analysts hold an analyst/industry conference call
Analyst Fernandez, along with Dr. Paul Gurbel and Dr. Richard Becker, discuss AstraZeneca's PEGASUS trial and the current use of Brilinta and dual antiplatelet therapy for prevention of CV disease and implications of the recently completed DAPT trial on an Analyst/Industry conference call to be held on January 21 at 1:30 pm.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use